Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SHR-1316 |
Trade Name | |
Synonyms | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 |
Drug Descriptions |
SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | NA |
NCIT ID | C148535 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + Nab-paclitaxel + SHR-1316 | Carboplatin Nab-paclitaxel SHR-1316 | 0 | 0 |
Fluorouracil + Liposomal irinotecan + SHR-1316 | Fluorouracil Liposomal irinotecan SHR-1316 | 0 | 0 |
Fluzoparib + SHR-1316 | Fluzoparib SHR-1316 | 0 | 0 |
IBI310 + SHR-1316 | IBI310 SHR-1316 | 0 | 0 |
SHR-1316 | SHR-1316 | 0 | 0 |
SHR-1316 + SHR-2002 | SHR-1316 SHR-2002 | 0 | 1 |
SHR-1316 + SHR1501 | SHR-1316 SHR1501 | 0 | 1 |